Because pramlintide is likely protected by patents, there are no generic versions of the drug available in the United States. The earliest a generic version could be expected is September 2015, when the next patent for the drug expires. In the meantime, do not purchase any so-called generic pramlintide -- such products are likely fake and could be dangerous.
Generic Pramlintide: An OverviewPramlintide acetate (Symlin®) is a prescription medication that has been licensed as a type 1 and type 2 diabetes treatment.
Pramlintide is manufactured by Amylin Pharmaceuticals, Inc. It is currently under the protection of a patent that prevents any generic pramlintide from being manufactured in the United States. Yet, if you search the Internet for "generic pramlintide," you may find a number of companies selling it. These medicines could be fake, substandard, and potentially dangerous.
There may be generic pramlintide available from another country, but there is really no way of knowing if such medications are genuine or not. Therefore, you should not buy any generic pramlintide until there is an approved generic available.
When Will Generic Pramlintide Be Available?
The first patents for pramlintide expired in March 2011 and September 2013. Yet, no generic versions are available. This strongly suggests that pramlintide is protected from generic competition by one or more later-expiring patents, the next of which is set to expire in September 2015 and the last of which is set to expire in March 2019.
September 2015 is the next predictable date that a generic version of pramlintide could become available. However, circumstances could shorten or extend the exclusivity period. This could include such things as other patents for specific pramlintide uses or lawsuits.